BDX
Becton, Dickinson and Company
BDX has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BDX overall, supported by stronger fundamentals and stronger modeled upside.
BDX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Healthy | |
| Under pressure |
BDX's profitability and cash flow are currently healthy, but its revenue and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BDX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $216 | — |
| Cheap | 36x | $119 | -45% |
| Fair | 46x | $152 | -30% |
| Current | 52x | $216 | — |
| Expensive | 62x | $204 | -5.3% |
Historical ranges are pointers, not guarantees.
BDX's PE is 52x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over BDX in the historical PE scenario, which offers more potential upside but is not a forecast.
BDX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect BDX's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over BDX on the outlook, with more favorable revenue expectations.
BDX Earnings Per Share
BDX and OSCR do not have enough comparable growth data to identify a winner.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
BDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5B | -9.5% |
| Q1 2026 | $4.7B | -11% |
| Q4 2025 | $5.3B | +1.6% |
| Q3 2025 | $5.9B | +8.4% |
| Q2 2025 | $5.5B | +10% |
| Q1 2025 | $5.3B | +4.5% |
| Q4 2024 | $5.2B | +9.8% |
| Q3 2024 | $5.4B | +6.9% |
BDX's revenue grew through 2023 and has held roughly level since: $5B last quarter, down 9.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 13% | -2.7 points |
| Q1 2026 | 2% | -8.4 points |
| Q4 2025 | 11% | +1.7 points |
| Q3 2025 | 12% | +0.4 points |
| Q2 2025 | 16% | +4 points |
| Q1 2025 | 10% | -4.2 points |
| Q4 2024 | 8.8% | -0.6 points |
| Q3 2024 | 11% | +4.6 points |
BDX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BDX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
BDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $633M | -39% |
| Q1 2026 | $546M | +1460% |
| Q4 2025 | $549M | -6.6% |
| Q3 2025 | $1B | +14% |
| Q2 2025 | $1B | -6.5% |
| Q1 2025 | $35M | -91% |
| Q4 2024 | $588M | -20% |
| Q3 2024 | $882M | -14% |
BDX's free cash flow has been positive every quarter for seven years: $2.7B over the past year, up 7.1% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BDX on cash flow, with more consistent year-over-year improvement.
BDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -5.5M shares |
| 1 year | -4.2% | -12.1M shares |
| 3 years | -4.4% | -12.8M shares |
| 5 years | -8% | -24M shares |
| Available history | -2.3% | -6.5M shares |
BDX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $2B |
| Q4 2025 | $250M |
| Q3 2025 | $250M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $750M |
| Q3 2024 | — |
BDX spent $2.5B buying back its own shares over the past year, about three times what it spent the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BDX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 3.7x | Elevated |
| Q1 2026 | 3.5x | Elevated |
| Q4 2025 | 3.7x | Elevated |
| Q3 2025 | 3.7x | Elevated |
| Q2 2025 | 3.8x | Elevated |
| Q1 2025 | 4.1x | High |
| Q4 2024 | 3.8x | Elevated |
| Q3 2024 | 3.9x | Elevated |
BDX's net debt is about 3.7 years of its operating earnings (EBITDA), about the same as a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over BDX on leverage, with a lower net debt burden relative to earnings.
BDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.7 | Overbought |
| Stochastic | 95.0 | Overbought |
BDX's weekly RSI is 74 (overbought) and its Stochastic is 95 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BDX PE vs Healthcare Sector
| Metric | BDX | Sector median | Relative |
|---|---|---|---|
| PE | 52x | 26x | 102% above |
| PE % | 74 | 29 | 45 pts above |
BDX is trading at 52x earnings, a 102% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over BDX on valuation relative to its sector.
BDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $195.1 | 11% above |
| 20 week MA | $181.8 | 19% above |
| 50 week MA | $166.8 | 29% above |
| 100 week MA | $161.5 | 34% above |
| 200 week MA | $176.9 | 22% above |
BDX has climbed back above all five of its weekly moving averages, and it's now 22% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
BDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $209.3 | $190.2 | -9.1% |
| 2021 | $190.2 | $190.9 | +0.4% |
| 2022 | $190.9 | $200.1 | +4.8% |
| 2023 | $200.1 | $191.7 | -4.2% |
| 2024 | $191.7 | $179.6 | -6.3% |
| 2025 | $179.6 | $154.4 | -14% |
| 2026 YTD | $154.4 | $215.7 | +40% |
BDX has finished three years in a row lower, and it's up 40% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BDX on returns for 2026, with the stronger performance.